BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis
Retrieved on:
Thursday, October 12, 2023
Diagnosis, Health, Highland, Pleural disease, Cancer, Disease, Lung cancer, Collaboration, Malignancy, Pleural cavity, Innovation, DNA, University, Neoplasm, NHS Highland, Immunology, Public, NHS, University of the Highlands and Islands, Lung, Infection, Nucleic acid thermodynamics, UHI, Patient, Medical imaging, Genetics
Edinburgh, UK – 12 October 2023 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptis – a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management – announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.
Key Points:
- Edinburgh, UK – 12 October 2023 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptis – a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management – announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.
- The study will involve a collaboration between BioCaptiva, University of the Highlands and Islands (UHI) and NHS Highland.
- The occurrence of cfDNA in exudative pleural fluid samples is well established, but it is often present in insufficient concentrations for sequencing to confirm a cancer diagnosis (versus benign disease).
- This route to diagnosis is particularly challenging for frail elderly patients and therefore improving the diagnostic utility of pleural fluid has both clinical and health economic benefits.